Barclays’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-76,659
| Closed | -$2.6M | – | 5362 |
|
|
2025
Q4 | $2.6M | Buy |
76,659
+76,564
| +80,594% | +$2.38M | ﹤0.01% | 2741 |
|
|
2025
Q3 | $2.45K | Buy |
95
+73
| +332% | +$955 | ﹤0.01% | 5134 |
|
|
2025
Q2 | $176 | Sell |
22
-4,350
| -99% | -$33.2K | ﹤0.01% | 5094 |
|
|
2025
Q1 | $42.7K | Sell |
4,372
-1,278
| -23% | -$12.6K | ﹤0.01% | 4658 |
|
|
2024
Q4 | $71.4K | Buy |
5,650
+684
| +14% | +$8.69K | ﹤0.01% | 4666 |
|
|
2024
Q3 | $79.9K | Buy |
4,966
+3,649
| +277% | +$73.8K | ﹤0.01% | 4628 |
|
|
2024
Q2 | $32.1K | Sell |
1,317
-10,260
| -89% | -$474K | ﹤0.01% | 4348 |
|
|
2024
Q1 | $832K | Buy |
11,577
+1,768
| +18% | +$246K | ﹤0.01% | 3263 |
|
|
2023
Q4 | $1.95M | Buy |
9,809
+3,103
| +46% | +$384K | ﹤0.01% | 2938 |
|
|
2023
Q3 | $892K | Sell |
6,706
-1,349
| -17% | -$220K | ﹤0.01% | 2413 |
|
|
2023
Q2 | $1.2M | Buy |
8,055
+1,801
| +29% | +$281K | ﹤0.01% | 2189 |
|
|
2023
Q1 | $918K | Sell |
6,254
-3,703
| -37% | -$749K | ﹤0.01% | 2794 |
|
|
2022
Q4 | $1.58M | Buy |
9,957
+4,329
| +77% | +$693K | ﹤0.01% | 2424 |
|
|
2022
Q3 | $1.08M | Buy |
5,628
+5,299
| +1,611% | +$1M | ﹤0.01% | 2169 |
|
|
2022
Q2 | $48K | Sell |
329
-2,967
| -90% | -$395K | ﹤0.01% | 4050 |
|
|
2022
Q1 | $580K | Buy |
+3,296
| New | +$623K | ﹤0.01% | 2800 |
|
Barclays's RAPT Position: Q1 2026 in Review
Barclays sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 76,659 shares — an estimated $2.6M sold.
Barclays first reported a position in RAPT in Q1 2022 and held it in 16 quarters. The position peaked at $2.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Barclays reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Barclays sold 76,659 RAPT Therapeutics shares in Q1 2026, an estimated $2.6M.
- Barclays first reported a position in RAPT Therapeutics in Q1 2022 and held it in 16 quarters.
- Barclays's RAPT Therapeutics position peaked at $2.6M in Q4 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.